Actionable news
0
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Merck carving out treatment niches in HCV with Zepatier; late-stage subgroup studies show cure rates as high as 96%

Results from two Phase 3 trials, C-EDGE IBLD and C-EDGE CO-STAR, show Merck's (NYSE:MRK) Zepatier (elbasvir/grazoprevir) achieved cure rates as high as 96% after 12 weeks of treatment in certain patients with chronic hepatitis C virus (HCV) infection. The data were presented at The International Liver Congress 2016 in Barcelona, Spain.

C-EDGE IBLD, a randomized, double-blind, placebo-controlled study evaluating Zepatier in patients...


More